The POSSIBILITY OF USING TUMOR NECROSIS FACTOR-THYMOSIN-α1 IN NEOADJUVANT CHEMOTHERAPY OF BREAST CANCER

Medical Council
doi 10.21518/2079-701x-2016-10-38-43
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Remedium, Ltd.

Related search

Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Neoadjuvant Chemotherapy in Breast Cancer

English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2018English

Assessment of a Breast Cancer Response to Neoadjuvant Chemotherapy Using Backscatter Ultrasound Statistics

2019English

Neoadjuvant Chemotherapy for Early Breast Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Indoleamine-2,3-Dioxygenase and Interleukin-6 Associated With Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy